Eutilex Co., Ltd. in Korea engineered a combination of a targeted hepatocellular carcinoma tumor (HCC) marker, Glypican-3 (GPC3), and an IL-18-secreting CAR T cell therapy (EU-307 GPC3-IL18) which is in Phase I and designated for the treatment of HCC and non-small cell lung carcinoma. The gene discussed is GPC3; the disease is hepatocellular carcinoma.